A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

FDA approves Novo Nordisk's semaglutide as obesity treatment

The US FDA has given the thumbs-up to Novo Nordisk's semaglutide as an injection-based treatment for obesity. This paves the way for massive sales for the Danish pharmaceutical company.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

There is an air of celebration at Novo Nordisk's headquarters, as the US Food and Drug Administration (FDA) has just approved the pharmaceutical company’s application for the use of semaglutide as a treatment for obesity marketed as Wegovy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • Jacob Sten Petersen, corporate vice president of stem cell research and development at Novo Nordisk | Photo: Novo Nordisk/PR

    New partnership may pave the way for first Novo Nordisk stem cell treatment

    For subscribers

  • Photo: Stine Tidsvilde

    FDA approval of semaglutide could help Novo Nordisk access unexploited obesity market

    For subscribers

  • Photo: Stine Tidsvilde

    Novo Nordisk enters collaboration with Heartseed on cell-based treatment

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers



Photo: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


Photo: Tom Little
Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers


Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers


Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers


  • Photo: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Photo: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


  • Photo: Staff/Reuters/Ritzau Scanpix

    Novo Nordisk suffers Wegovy defeat to Viatris in patent court

    It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

  • Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr

    Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

    The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

    For subscribers


  • Photo: Novo Nordisk / Pr

    Pharmaceutical industry to grow 4% annually towards 2030

    However, there is one company in the manufacturing sector that is predicted to see negative growth. 

    For subscribers


Further reading

Photo: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers


Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.


Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Photo: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers


Jobs

  • Senior Legal Councel

  • Project Director, HR & ESG

  • Audit & Supplier Manager

  • Clinical Trial Manager

  • Chemist for Incoming Materials in QC department

  • Clinical Supply Manager

  • Director, Head of Antibody Technology

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Senior QA Specialists (GMP or GCP)

  • Discovery Project Leader, Principal Scientist

  • Senior CMC Specialist, Upstream Processing, Genmab

  • QA/RA Manager

  • Scientist - Bioanalysis, Biologics

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Senior Legal Councel

  • Project Director, HR & ESG

  • Audit & Supplier Manager

  • Clinical Trial Manager

  • Chemist for Incoming Materials in QC department

  • Clinical Supply Manager

  • Director, Head of Antibody Technology

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

  • VP of Software Development, Perfusion Tech

  • Senior QA Specialists (GMP or GCP)

  • Discovery Project Leader, Principal Scientist

  • Senior CMC Specialist, Upstream Processing, Genmab

  • QA/RA Manager

  • Scientist - Bioanalysis, Biologics

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved